I
Description
ILYA Pharma is a Swedish biotech company based in Uppsala developing next-generation biological drugs for skin and mucosal wound healing. Its platform uses genetically engineered lactic acid bacteria as vectors delivering CXCL12 on-site. ILP100-Topical has completed a Phase I/II trial with positive results. FDA granted Rare Paediatric Disease Designation (RPDD) for SAVI. Raised $18.4M.